Search

University of Minnesota Kinase Degradation Compounds for Cancer Treatment

USPTO granted Patent US12605452B2 to the Regents of the University of Minnesota on April 21, 2026. The patent covers compounds of Formula (I) or (II) comprising Aurora A or CDK4/6 ligands linked to E3 ligase ligands, along with pharmaceutical compositions and methods for treating cancer using such compounds. The patent contains 13 claims.